MedDataX Logo

Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.

NCT ID: NCT00290901

Last Updated: 2021-03-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

754 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain

NCT02367820

Low Back Pain Chronic Pain
COMPLETED PHASE3

Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

NCT01789970

Low Back Pain
COMPLETED PHASE3

Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

NCT00761150

Chronic Low Back Pain
COMPLETED PHASE3

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

NCT00449176

Low Back Pain
COMPLETED PHASE3

Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

NCT00763321

Chronic Low Back Pain
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tramadol Hydrochloride 50mg

Intervention Type DRUG

Celebrex 200mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject presents with duration of chronic low back pain of \> 3 months requiring regular use of analgesics (\> 4 days/week), except for acetaminophen which cannot have been the sole analgesic used.

Exclusion Criteria

* The subject has chronic low back pain, which is neurologic in etiology (i.e., radiculopathy, neuropathy, myelopathy)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Phoenix, Arizona, United States

Site Status

Pfizer Investigational Site

Scottsdale, Arizona, United States

Site Status

Pfizer Investigational Site

Tucson, Arizona, United States

Site Status

Pfizer Investigational Site

Little Rock, Arkansas, United States

Site Status

Pfizer Investigational Site

Anaheim, California, United States

Site Status

Pfizer Investigational Site

La Mesa, California, United States

Site Status

Pfizer Investigational Site

Long Beach, California, United States

Site Status

Pfizer Investigational Site

Oceanside, California, United States

Site Status

Pfizer Investigational Site

Paramount, California, United States

Site Status

Pfizer Investigational Site

Sacramento, California, United States

Site Status

Pfizer Investigational Site

San Francisco, California, United States

Site Status

Pfizer Investigational Site

San Luis Obispo, California, United States

Site Status

Pfizer Investigational Site

Tustin, California, United States

Site Status

Pfizer Investigational Site

Vista, California, United States

Site Status

Pfizer Investigational Site

Boulder, Colorado, United States

Site Status

Pfizer Investigational Site

Colorado Springs, Colorado, United States

Site Status

Pfizer Investigational Site

Denver, Colorado, United States

Site Status

Pfizer Investigational Site

Cos Cob, Connecticut, United States

Site Status

Pfizer Investigational Site

Washington D.C., District of Columbia, United States

Site Status

Pfizer Investigational Site

Miami, Florida, United States

Site Status

Pfizer Investigational Site

Pembroke Pines, Florida, United States

Site Status

Pfizer Investigational Site

West Palm Beach, Florida, United States

Site Status

Pfizer Investigational Site

Decatur, Georgia, United States

Site Status

Pfizer Investigational Site

Woodstock, Georgia, United States

Site Status

Pfizer Investigational Site

Libertyville, Illinois, United States

Site Status

Pfizer Investigational Site

Morton Grove, Illinois, United States

Site Status

Pfizer Investigational Site

Arkansas City, Kansas, United States

Site Status

Pfizer Investigational Site

Overland Park, Kansas, United States

Site Status

Pfizer Investigational Site

Wichita, Kansas, United States

Site Status

Pfizer Investigational Site

Madisonville, Kentucky, United States

Site Status

Pfizer Investigational Site

Baltimore, Maryland, United States

Site Status

Pfizer Investigational Site

Wheaton, Maryland, United States

Site Status

Pfizer Investigational Site

Jackson, Mississippi, United States

Site Status

Pfizer Investigational Site

Kansas City, Missouri, United States

Site Status

Pfizer Investigational Site

St Louis, Missouri, United States

Site Status

Pfizer Investigational Site

Omaha, Nebraska, United States

Site Status

Pfizer Investigational Site

Brooklyn, New York, United States

Site Status

Pfizer Investigational Site

New York, New York, United States

Site Status

Pfizer Investigational Site

Rochester, New York, United States

Site Status

Pfizer Investigational Site

Raleigh, North Carolina, United States

Site Status

Pfizer Investigational Site

Medford, Oregon, United States

Site Status

Pfizer Investigational Site

Portland, Oregon, United States

Site Status

Pfizer Investigational Site

Camp Hill, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Duncansville, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Charleston, South Carolina, United States

Site Status

Pfizer Investigational Site

Columbia, South Carolina, United States

Site Status

Pfizer Investigational Site

Johnson City, Tennessee, United States

Site Status

Pfizer Investigational Site

New Tazewell, Tennessee, United States

Site Status

Pfizer Investigational Site

Austin, Texas, United States

Site Status

Pfizer Investigational Site

San Angelo, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

Arlington, Virginia, United States

Site Status

Pfizer Investigational Site

Danville, Virginia, United States

Site Status

Pfizer Investigational Site

Rio Piedras, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Puerto Rico

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3191165&StudyName=Celebrex+vs+Tramadol+in+the+treatment+of+chronic+lower+back+pain%2E+

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A3191165

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain
NCT00594516 COMPLETED PHASE3
A Study of Pain Relief in Low Back Pain
NCT00325949 COMPLETED PHASE3
Phase 2 Chronic Low Back Pain Study
NCT01364922 COMPLETED PHASE2
Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain
NCT01081912 COMPLETED PHASE3
Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain
NCT02716857 COMPLETED PHASE3
A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain
NCT00364546 COMPLETED PHASE3
Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin
NCT01352741 COMPLETED PHASE4
Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.
NCT01725087 COMPLETED PHASE2
Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
NCT02603705 COMPLETED PHASE3
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548
NCT05455502 COMPLETED PHASE1
Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time
NCT01240863 COMPLETED PHASE3
Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets
NCT01922739 COMPLETED PHASE3
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes
NCT01177280 COMPLETED
Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain
NCT01344720 UNKNOWN PHASE4
A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
NCT00361504 COMPLETED PHASE3
Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain
NCT00195728 COMPLETED PHASE3
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
NCT00983385 COMPLETED PHASE3
Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers
NCT02259179 COMPLETED PHASE1
A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
NCT00486811 COMPLETED PHASE3
Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)
NCT01685684 COMPLETED PHASE3
A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users
NCT03757559 COMPLETED PHASE1
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
NCT00487435 COMPLETED PHASE3
Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.
NCT01838616 COMPLETED PHASE4
Low-Dose Naltrexone and Acetaminophen Combination in the Treatment of Chronic Low Back Pain (ANODYNE-4)
NCT03201393 COMPLETED PHASE2
A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet
NCT01758978 COMPLETED PHASE1